跳到正文
原文
Eric Topol· @EricTopol · X·· 47 分钟前精选AI 评分65
AI 导读

Eric Topol 引用报道称,一项急性髓系白血病(AML)疫苗的II期随机试验显示死亡风险降低41%,生存期延长近一年。他同时提到,个体化mRNA新抗原疫苗在胰腺癌、三阴性乳腺癌和非小细胞肺癌中已出现成功迹象,并引用了一篇关于mRNA疫苗在黑色素瘤III期随机试验中取得成功的报道。

推荐理由

这条内容把AML疫苗II期随机试验的死亡风险下降与生存延长数据,放进个体化mRNA肿瘤疫苗近期多项进展的脉络里。

正文

Now add success for an acute myelogenous leukemia (AML) vaccine, a 41% reduction of death, extending survival for nearly a year, a Phase 2 randomized trial
https://www.fiercebiotech.com/biotech/sellas-marks-nine-month-survival-benefit-late-stage-leukemia-vaccine-study

引用Eric Topol@EricTopol
The mRNA vaccine success vs melanoma in a Phase definitive 3 randomized trial today is on top of signs of success for personalized mRNA neoantigen vaccines vs pancreatic cancer, triple negative breast cancer, and non-small cell lung cancer https://www.wsj.com/health/pharma/moderna-merck-vaccine-succeeds-in-preventing-melanoma-from-returning-540e9e18?st=gfUmoY&reflink=desktopwebshare_permalink
在 X 查看被引用的帖子

来源:Eric Topol · x.com